Projekt per år
Sammanfattning
Introduction: Gene therapy is becoming increasingly common in clinical practice, giving hope for the correction of a wide range of human diseases and defects. The CRISPR/Cas9 system, consisting of the Cas9 nuclease and single-guide RNA (sgRNA), has revolutionized the field of gene editing. However, efficiently delivering the CRISPR-Cas9 to the target organ or cell remains a significant challenge. In recent years, with rapid advances in nanoscience, materials science, and medicine, researchers have developed various technologies that can deliver CRISPR-Cas9 in different forms for in vitro and in vivo gene editing. Here, we review the development of the CRISPR-Cas9 and describe the delivery forms and the vectors that have emerged in CRISPR-Cas9 delivery, summarizing the key barriers and the promising strategies that vectors currently face in delivering the CRISPR-Cas9. Areas covered: With the rapid development of CRISPR-Cas9, delivery methods are becoming increasingly important in the in vivo delivery of CRISPR-Cas9. Expert opinion: CRISPR-Cas9 is becoming increasingly common in clinical trials. However, the complex nuclease and protease environment is a tremendous challenge for in vivo clinical applications. Therefore, the development of delivery methods is highly likely to take the application of CRISPR-Cas9 technology to another level.
Originalspråk | Engelska |
---|---|
Sidor (från-till) | 913-926 |
Antal sidor | 14 |
Tidskrift | Expert Opinion on Drug Delivery |
Volym | 19 |
Nummer | 8 |
DOI | |
Status | Publicerad - 17 juli 2022 |
MoE-publikationstyp | A2 Granska artikel i en vetenskaplig tidskrift |
Fingeravtryck
Fördjupa i forskningsämnen för ”Progress of delivery methods for CRISPR-Cas9”. Tillsammans bildar de ett unikt fingeravtryck.Projekt
- 2 Aktiv
-
FCFH: Finland-China Network in Food and Health Sciences
Rosenholm, J., Xu, C. & Zhang, H.
Undervisnings och kulturministeriet i Finland (UKM)
01/01/21 → 31/12/24
Projekt: Ministerier / Statliga myndigheter och verk
-
Targeted delivery of CRISPR/Cas9 for advanced liver cancer therapy through c-Myc knockout
01/09/19 → 31/08/24
Projekt: FA/Övriga Forskningsråd